AC
CLVS

Argentiere Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Argentiere Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20,000
Closed -$587K – 97
2018
Q3 		$587K Sell
20,000
-50,000
-71% -$1.94M 0.06% 75
2018
Q2 		$3.18M Buy
70,000
+10,000
+17% +$486K 1.23% 17
2018
Q1 		$3.17M Buy
60,000
+25,000
+71% +$1.46M 1.35% 20
2017
Q4 		$2.38M Sell
35,000
-5,000
-13% -$350K 1.47% 14
2017
Q3 		$3.3M Buy
+40,000
New +$3.17M 1.27% 15

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Argentiere Capital's CLVS Position: Q4 2018 in Review

Argentiere Capital sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 20,000 shares — an estimated $587K sold.

Argentiere Capital first reported a position in CLVS in Q3 2017 and held it in 5 quarters. The position peaked at $3.3M in Q3 2017. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

  • Argentiere Capital reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
  • Argentiere Capital sold 20,000 Clovis Oncology, Inc. shares in Q4 2018, an estimated $587K.
  • Argentiere Capital first reported a position in Clovis Oncology, Inc. in Q3 2017 and held it in 5 quarters.
  • Argentiere Capital's Clovis Oncology, Inc. position peaked at $3.3M in Q3 2017.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Argentiere Capital's 13F filing for Q4 2018, filed 14 Feb 2019.